Gordon V Ohning, Gustavo A Machicado, Dennis M Jensen
{"title":"Definitive therapy for internal hemorrhoids--new opportunities and options.","authors":"Gordon V Ohning, Gustavo A Machicado, Dennis M Jensen","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Hemorrhoids are common in Western societies. Appropriate assessment and treatment of symptomatic hemorrhoids can substantially reduce morbidity and improve patient well-being. In this article, the clinical presentation, differential diagnoses, and current treatment options, including the CRH-O'Regan banding device, an emerging technology for the anoscopic treatment of symptomatic internal hemorrhoids, are reviewed.</p>","PeriodicalId":21173,"journal":{"name":"Reviews in gastroenterological disorders","volume":"9 1","pages":"16-26"},"PeriodicalIF":0.0,"publicationDate":"2009-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"28109193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Tatyana A Shamliyan, Donna Z Bliss, Jing Du, Ryan Ping, Timothy J Wilt, Robert L Kane
{"title":"Prevalence and risk factors of fecal incontinence in community-dwelling men.","authors":"Tatyana A Shamliyan, Donna Z Bliss, Jing Du, Ryan Ping, Timothy J Wilt, Robert L Kane","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Fecal incontinence (FI) in community-dwelling men affects quality of life and increases the risk of institutionalization. Observational studies and randomized, controlled trials (RCTs) on epidemiology and prevention of FI published in English from 1990 to November 2007 were identified in several databases to abstract rates and adjusted odds ratios (ORs) of incontinence and to synthesize evidence with random effects models. Twenty-one observational studies and 4 RCTs were eligible for analysis. Pooled prevalence of FI in elderly men increased with age to 5% to 6%. Men over age 85 years (OR 2.5; 95% confidence interval [CI], 1.3-5) and with kidney diseases (OR 1.9; 95% CI, 1.2-3.3) had higher odds of incident FI. Significantly impaired cognitive status and general health were associated with FI. Men had increased risk of incontinence after radical prostatectomy or radiation for prostate cancer. Lower doses of radiation caused inconsistent reduction in FI across 2 RCTs. The prevalence of incontinence increased with age and functional dependency. Cognitive impairment, poor general health, surgery, and radiation for prostate cancer were associated with incontinence in community-dwelling men. No effective interventions are known at the present time.</p>","PeriodicalId":21173,"journal":{"name":"Reviews in gastroenterological disorders","volume":"9 4","pages":"E97-110"},"PeriodicalIF":0.0,"publicationDate":"2009-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"28639727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Screening and diagnosis of cholangiocarcinoma in patients with primary sclerosing cholangitis.","authors":"Arun B Jesudian, Ira M Jacobson","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Primary sclerosing cholangitis (PSC) is an idiopathic cholestatic liver disease which predisposes to the development of cholangiocarcinoma (CCA). Detection of CCA in PSC patients remains difficult and CCA is often found incidentally at autopsy or in explanted livers post-transplantation for PSC. In addition, considerable overlap exists between the symptoms of CCA and those of benign dominant strictures encountered commonly in PSC. Clinicians utilize a combination of serum tumor markers, cytology from bile duct brushings, and imaging in an attempt to screen for and detect CCA in patients with PSC, although the evidence for these modalities remains largely retrospective. Newer treatment options for early CCA such as resection and liver transplantation have shown promising results, making an effective screening regimen for the detection of CCA at a treatable stage in PSC patients a highly coveted goal.</p>","PeriodicalId":21173,"journal":{"name":"Reviews in gastroenterological disorders","volume":" ","pages":"E41-7"},"PeriodicalIF":0.0,"publicationDate":"2009-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40024564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Diarrhea. Best option for traveler's diarrhea: loperamide plus an antibiotic?","authors":"Edward C Oldfield","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":21173,"journal":{"name":"Reviews in gastroenterological disorders","volume":" ","pages":"E63-4"},"PeriodicalIF":0.0,"publicationDate":"2009-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40024567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Diarrhea. Enterotoxigenic Bacteroides fragilis: newly recognized cause of inflammatory diarrhea.","authors":"Edward C Oldfield","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":21173,"journal":{"name":"Reviews in gastroenterological disorders","volume":"9 2","pages":"E65-6"},"PeriodicalIF":0.0,"publicationDate":"2009-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"28338649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Peptic ulcer bleeding following therapeutic endoscopy: a new indication for intravenous esomeprazole.","authors":"Danial E Baker","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Intravenous (IV) administration of the esomeprazole is a faster way to achieve gastric acid suppression than oral administration of the same agent. Peak suppression following IV administration occurs within hours compared with several days following oral administration. Thus, the IV administration route offers a faster onset of gastric suppression, achievement of intragastric pH closer to target levels, and better bioavailability. Treatment of peptic ulcer bleeding is the newest indication for the IV formulation of esomeprazole. The drug is effective in preventing rebleeds following endoscopic treatment when administered within 24 hours of the procedure as an 80-mg bolus followed by an IV infusion for 72 hours. What remains to be seen is whether oral therapy can be substituted for all, or part, of the 72-hour IV infusion and whether the patient can be discharged from the hospital sooner with similar outcomes.</p>","PeriodicalId":21173,"journal":{"name":"Reviews in gastroenterological disorders","volume":"9 4","pages":"E111-8"},"PeriodicalIF":0.0,"publicationDate":"2009-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"28639724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Bifidobacterium infantis 35624: a novel probiotic for the treatment of irritable bowel syndrome.","authors":"Darren M Brenner, William D Chey","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Irritable bowel syndrome (IBS) is a common disorder with widespread prevalence. Due to its heterogeneous pathogenesis, efficacious treatments are lacking. The few medications that are effective for treating global IBS symptoms have either been withdrawn or restricted due to detrimental side effects; thus, safe and effective alternatives are urgently needed. Increasing data have revealed that inflammatory changes may play a role in the development of IBS, and probiotics, commensal organisms with inherent health benefits, may alter that milieu. Although their exact mechanisms of action remain elusive, it is clear that the beneficial properties inherent to each probiotic species are strain specific. Bifidobacterium infantis 35624 ( B infantis 35624; Bifantis, The Procter & Gamble Company, Cincinnati, OH), is a probiotic with unique abilities to reduce intestinal inflammation. Two randomized, controlled trials have validated its efficacy for treating both individual and global IBS symptoms without evidence to suggest an increase in adverse events. B. infantis 35624 appears safe and effective for the treatment of IBS.</p>","PeriodicalId":21173,"journal":{"name":"Reviews in gastroenterological disorders","volume":"9 1","pages":"7-15"},"PeriodicalIF":0.0,"publicationDate":"2009-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"28109192","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The future of inflammatory bowel disease care.","authors":"William J Sandborn","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>This article summarizes the David Sun Lecture at the American College of Gastroenterology in Orlando, Florida, that was delivered on October 4, 2008. The lecture, entitled \"The Future Direction of IBD Care,\" reviewed the future use of current drugs (such as 5-aminosalicylate, steroids, immunosuppressive medications, and biologic agents) and upcoming drugs in the treatment of IBD.</p>","PeriodicalId":21173,"journal":{"name":"Reviews in gastroenterological disorders","volume":"9 3","pages":"E69-77"},"PeriodicalIF":0.0,"publicationDate":"2009-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"28495754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}